Cargando…
Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis
BACKGROUND: Interleukin-15 (IL-15) is thought to be involved in the physiopathological mechanisms of RA and it can be detected in the serum and the synovial fluid of inflamed joints in patients with RA but not in patients with osteoarthritis or other inflammatory joint diseases. Therefore, the objec...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248461/ https://www.ncbi.nlm.nih.gov/pubmed/22242124 http://dx.doi.org/10.1371/journal.pone.0029492 |
_version_ | 1782220248802394112 |
---|---|
author | González-Álvaro, Isidoro Ortiz, Ana M. Alvaro-Gracia, José María Castañeda, Santos Díaz-Sánchez, Belen Carvajal, Inmaculada García-Vadillo, J. Alberto Humbría, Alicia López-Bote, J. Pedro Patiño, Esther Tomero, Eva G. Vicente, Esther F. Sabando, Pedro García-Vicuña, Rosario |
author_facet | González-Álvaro, Isidoro Ortiz, Ana M. Alvaro-Gracia, José María Castañeda, Santos Díaz-Sánchez, Belen Carvajal, Inmaculada García-Vadillo, J. Alberto Humbría, Alicia López-Bote, J. Pedro Patiño, Esther Tomero, Eva G. Vicente, Esther F. Sabando, Pedro García-Vicuña, Rosario |
author_sort | González-Álvaro, Isidoro |
collection | PubMed |
description | BACKGROUND: Interleukin-15 (IL-15) is thought to be involved in the physiopathological mechanisms of RA and it can be detected in the serum and the synovial fluid of inflamed joints in patients with RA but not in patients with osteoarthritis or other inflammatory joint diseases. Therefore, the objective of this work is to analyse whether serum IL-15 (sIL-15) levels serve as a biomarker of disease severity in patients with early arthritis (EA). METHODOLOGY AND RESULTS: Data from 190 patients in an EA register were analysed (77.2% female; median age 53 years; 6-month median disease duration at entry). Clinical and treatment information was recorded systematically, especially the prescription of disease modifying anti-rheumatic drugs. Two multivariate longitudinal analyses were performed with different dependent variables: 1) DAS28 and 2) a variable reflecting intensive treatment. Both included sIL-15 as predictive variable and other variables associated with disease severity, including rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA). Of the 171 patients (638 visits analysed) completing the follow-up, 71% suffered rheumatoid arthritis and 29% were considered as undifferentiated arthritis. Elevated sIL-15 was detected in 29% of this population and this biomarker did not overlap extensively with RF or ACPA. High sIL-15 levels (β Coefficient [95% confidence interval]: 0.12 [0.06–0.18]; p<0.001) or ACPA (0.34 [0.01–0.67]; p = 0.044) were significantly and independently associated with a higher DAS28 during follow-up, after adjusting for confounding variables such as gender, age and treatment. In addition, those patients with elevated sIL-15 had a significantly higher risk of receiving intensive treatment (RR 1.78, 95% confidence interval 1.18–2.7; p = 0.007). CONCLUSIONS: Patients with EA displaying high baseline sIL-15 suffered a more severe disease and received more intensive treatment. Thus, sIL-15 may be a biomarker for patients that are candidates for early and more intensive treatment. |
format | Online Article Text |
id | pubmed-3248461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32484612012-01-12 Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis González-Álvaro, Isidoro Ortiz, Ana M. Alvaro-Gracia, José María Castañeda, Santos Díaz-Sánchez, Belen Carvajal, Inmaculada García-Vadillo, J. Alberto Humbría, Alicia López-Bote, J. Pedro Patiño, Esther Tomero, Eva G. Vicente, Esther F. Sabando, Pedro García-Vicuña, Rosario PLoS One Research Article BACKGROUND: Interleukin-15 (IL-15) is thought to be involved in the physiopathological mechanisms of RA and it can be detected in the serum and the synovial fluid of inflamed joints in patients with RA but not in patients with osteoarthritis or other inflammatory joint diseases. Therefore, the objective of this work is to analyse whether serum IL-15 (sIL-15) levels serve as a biomarker of disease severity in patients with early arthritis (EA). METHODOLOGY AND RESULTS: Data from 190 patients in an EA register were analysed (77.2% female; median age 53 years; 6-month median disease duration at entry). Clinical and treatment information was recorded systematically, especially the prescription of disease modifying anti-rheumatic drugs. Two multivariate longitudinal analyses were performed with different dependent variables: 1) DAS28 and 2) a variable reflecting intensive treatment. Both included sIL-15 as predictive variable and other variables associated with disease severity, including rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA). Of the 171 patients (638 visits analysed) completing the follow-up, 71% suffered rheumatoid arthritis and 29% were considered as undifferentiated arthritis. Elevated sIL-15 was detected in 29% of this population and this biomarker did not overlap extensively with RF or ACPA. High sIL-15 levels (β Coefficient [95% confidence interval]: 0.12 [0.06–0.18]; p<0.001) or ACPA (0.34 [0.01–0.67]; p = 0.044) were significantly and independently associated with a higher DAS28 during follow-up, after adjusting for confounding variables such as gender, age and treatment. In addition, those patients with elevated sIL-15 had a significantly higher risk of receiving intensive treatment (RR 1.78, 95% confidence interval 1.18–2.7; p = 0.007). CONCLUSIONS: Patients with EA displaying high baseline sIL-15 suffered a more severe disease and received more intensive treatment. Thus, sIL-15 may be a biomarker for patients that are candidates for early and more intensive treatment. Public Library of Science 2011-12-29 /pmc/articles/PMC3248461/ /pubmed/22242124 http://dx.doi.org/10.1371/journal.pone.0029492 Text en González-Álvaro et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article González-Álvaro, Isidoro Ortiz, Ana M. Alvaro-Gracia, José María Castañeda, Santos Díaz-Sánchez, Belen Carvajal, Inmaculada García-Vadillo, J. Alberto Humbría, Alicia López-Bote, J. Pedro Patiño, Esther Tomero, Eva G. Vicente, Esther F. Sabando, Pedro García-Vicuña, Rosario Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis |
title | Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis |
title_full | Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis |
title_fullStr | Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis |
title_full_unstemmed | Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis |
title_short | Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis |
title_sort | interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248461/ https://www.ncbi.nlm.nih.gov/pubmed/22242124 http://dx.doi.org/10.1371/journal.pone.0029492 |
work_keys_str_mv | AT gonzalezalvaroisidoro interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT ortizanam interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT alvarograciajosemaria interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT castanedasantos interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT diazsanchezbelen interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT carvajalinmaculada interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT garciavadillojalberto interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT humbriaalicia interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT lopezbotejpedro interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT patinoesther interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT tomeroevag interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT vicenteestherf interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT sabandopedro interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis AT garciavicunarosario interleukin15levelsinserummaypredictaseverediseasecourseinpatientswithearlyarthritis |